A Phase 4 interventional study of Ranibizumab in Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 7th largest by enrollment, is one of 6 that started in 2013, is one of 12 in phase 4, and was the 38th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 349 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
29 studies in Choroidal Neovascularization by Novartis: none open now, none under way, none of them phase 3. Of 29 finished, 22 (76%) have results posted.
Among the 29 studies in Choroidal Neovascularization by Novartis, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2013, is one of 8 in phase 4, and was the 20th registered.
Novartis’s Choroidal Neovascularization studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 29 in Choroidal Neovascularization:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection. The results will be used to generate recommendations about ranibizumab treatment when using an 'inject and extend' approach to maximise patient outcomes, while reducing the need for potentially unnecessary intravitreal injections. This study will also investigate if genotypic expression influences response to intravitreal injections of ranibizumab between the two treatment arms.
The study hypothesis is that intravitreal ranibizumab when administered to resolve IRF (and/or SRF >200 μm at the foveal centre) results in visual acuity benefit that is not clinically worse than intravitreal ranibizumab when administered to completely resolve both IRF and SRF in patients with wet AMD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
Drug: Ranibizumab
Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF \>200 um on OCT.
Drug: Ranibizumab
Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
Also known as: LUCENTIS
Mean Change in Best-corrected Visual Acuity (BCVA) From Baseline to 24 Months.
Best-corrected visual acuity (BCVA) with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and month 24.
Time frame: Baseline to month 24
Mean Change in BCVA From Baseline to Month 12.
Best-corrected visual acuity (BCVA) with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and month 12.
Time frame: Baseline to month 12
Mean Change in Central Retinal Thickness (CRT) From Baseline to Month 12 and 24.
Central retinal thickness will be measured by Optical Coherence Tomography (OCT) at every visit.
Time frame: Baseline to month 12 and month 24
Mean Number of Injections From Baseline to Month 12 and 24
The number of injections will be determined by the individual patient response to ranibizumab therapy and potential for extension between injections based on specific criteria: loss of visual acuity, new retinal haemorrhage, and presence of IRF or SRF on OCT.
Time frame: Baseline to month 12 to month 24.
Mean Change in Area of New and Existing Geographic Atrophy From Baseline to Month 12 and 24.
Autofluorescence will be measured by multimodal imaging to assess the presence and development of geographic atrophy in the study at baseline, and month 12 and 24.
Time frame: Baseline to months 12 and 24.
Proportion of Patients Showing Newly Developed Geographic Atrophy (GA) at Months 12 and 24
A multimodal imaging approach will be used to assess the presence of new geographic atrophy (defined as incorporating both geographic atrophy and atrophy associated with the CNV) in the study eye at baseline, and month 12 and 24. Image modalities will include fundus autofluorescence (AF) imaging, infrared imaging, OCT and colour fundus (CF) photographs. Atrophy will be diagnosed if FA and one other modality confirm the presence of macular atrophy
Time frame: Months 12 and 24
Proportion of Patients Showing no IRF and SRF at Months 2, 12 and 24.
Assessed by Optical Coherence Tomography (OCT) and confirmed by a central reading centre.
Time frame: Months 2, 12 and 24.
Proportion of Patients Showing Greater Than or Equal to 15 Letters Early Treatment Diabetic Retinopathy (ETDRS) Gain From Baseline to Month 12 and 24.
Best-corrected visual acuity (BCVA) with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and months 2, 12 and 24.
Time frame: Baseline to months 12 and 24.
Proportion of Patients Showing Less Than 15 Letters ETDRS Loss From Baseline to Month 12 and 24.
Best-corrected visual acuity with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and months 2, 12 and 24.
Time frame: Baseline to months 12 and 24
Number of Participants With the Genotypes Associated With Age-Related Macular Degeneration (AMD) and Response to Treatment at Baseline; Correlation With Visual Acuity (VA) Outcome and Ability to Dry the Retina.
DNA will be extracted from saliva and genotyping performed on the significantly associated single nucleotide polymorphisms (SNPs) identified by the AMD Gene Consortium (Nature Genetics, March 2013). Genotypes will be derived through the use of a Sequenom Iplex protocol. No correlation analyses were performed.
Time frame: Baseline or following consent
Proportion of Patients With Both SRF (Sub-retinal Fluid) and IRF (Intra-retinal Fluid) Who Despite Monthly Treatment do Not Resolve Their SRF
Assessed by Optical Coherence Tomography (OCT) and confirmed by a central reading centre.
Time frame: Month 12 and 24
The Number of Times a Participant Needs to Return to Monthly Treatments During the 24 Months.
Treatment requirements will be determined by the individual patient disease activity as measured by OCT, BCVA, colour fundus photography and fluorescein angiography (FA). Analysis was not performed.
Time frame: Month 24
a total of 349 subjects were randomized to the study (intensive arm, 174; relaxed arm, 175). relaxed 173).
| Milestone | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Started | 174 | 175 |
| Completed | 134 | 145 |
| Not completed | 40 | 30 |
| Withdrew: Adverse event | 11 | 4 |
| Withdrew: Subject withdrew consent | 14 | 12 |
| Withdrew: Lost to follow-up | 4 | 7 |
| Withdrew: Death | 7 | 5 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Physician decision | 3 | 2 |
Best-corrected visual acuity (BCVA) with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and month 24.
| Letters | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Mean Change in Best-corrected Visual Acuity (BCVA) From Baseline to 24 Months. | 3.2 ± 16.51 | 2.5 ± 16.56 |
Best-corrected visual acuity (BCVA) with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and month 12.
| Letters | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Mean Change in BCVA From Baseline to Month 12. | 4.6 ± 14.69 | 3.9 ± 12.73 |
Central retinal thickness will be measured by Optical Coherence Tomography (OCT) at every visit.
| μm | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12 | -147.1 ± 168.33 | -125.6 ± 133.08 |
| Month 24 | -158.9 ± 170.44 | -126.9 ± 140.01 |
The number of injections will be determined by the individual patient response to ranibizumab therapy and potential for extension between injections based on specific criteria: loss of visual acuity, new retinal haemorrhage, and presence of IRF or SRF on OCT.
| Injections | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12 | 9.5 ± 2.60 | 8.9 ± 2.25 |
| Month 24 | 17 ± 6.48 | 15.8 ± 5.91 |
Autofluorescence will be measured by multimodal imaging to assess the presence and development of geographic atrophy in the study at baseline, and month 12 and 24.
| mm^2 | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12 | 0.8 ± 2.13 | 0.7 ± 1.80 |
| Month 24 | 1.5 ± 3.18 | 1.2 ± 2.62 |
A multimodal imaging approach will be used to assess the presence of new geographic atrophy (defined as incorporating both geographic atrophy and atrophy associated with the CNV) in the study eye at baseline, and month 12 and 24. Image modalities will include fundus autofluorescence (AF) imaging, infrared imaging, OCT and colour fundus (CF) photographs. Atrophy will be diagnosed if FA and one other modality confirm the presence of macular atrophy
| Participants | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12, GA present | 25 | 18 |
| Month 12, GA absent | 103 | 110 |
| Month 24, GA present | 32 | 29 |
| Month 24, GA absent | 80 | 94 |
Assessed by Optical Coherence Tomography (OCT) and confirmed by a central reading centre.
| Participants | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 2 | 106 | 93 |
| month 12 | 87 | 72 |
| Month 24 | 64 | 56 |
Best-corrected visual acuity (BCVA) with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and months 2, 12 and 24.
| Participants | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12 | 29 | 24 |
| Month 24 | 25 | 24 |
Best-corrected visual acuity with refraction will be taken using a logMAR chart at a distance of 3 metres in the study eye at baseline and months 2, 12 and 24.
| Participants | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12 | 142 | 141 |
| Month 24 | 129 | 132 |
DNA will be extracted from saliva and genotyping performed on the significantly associated single nucleotide polymorphisms (SNPs) identified by the AMD Gene Consortium (Nature Genetics, March 2013). Genotypes will be derived through the use of a Sequenom Iplex protocol. No correlation analyses were performed.
| Participants | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| RS10490924 GG | 44 | 47 |
| RS10490924 GT | 56 | 57 |
| RS10490924 TT | 24 | 23 |
| RS1061170 CC | 35 | 43 |
| RS1061170 CT | 61 | 61 |
| RS1061170 TT | 29 | 21 |
| RS10737680 AA | 68 | 82 |
| RS10737680 AC | 48 | 37 |
| RS10737680 CC | 9 | 8 |
| RS11200638 AA | 21 | 23 |
| RS11200638 AG | 58 | 58 |
| RS11200638 GG | 46 | 46 |
| RS121913059 CC | 124 | 127 |
| RS121913059 CT | 1 | 0 |
| RS13278062 GG | 29 | 17 |
| RS13278062 GT | 60 | 75 |
| RS13278062 TT | 36 | 35 |
| RS141853578 CC | 125 | 125 |
| RS147859257 GT | 2 | 1 |
| RS147859257 TT | 123 | 126 |
| RS1864163 AA | 9 | 7 |
| RS1864163 AG | 29 | 46 |
| RS1864163 GG | 85 | 73 |
| RS2230199 CC | 81 | 67 |
| RS2230199 CG | 37 | 52 |
| RS2230199 GG | 6 | 8 |
| RS3130783 AA | 77 | 91 |
| RS3130783 AG | 44 | 32 |
| RS3130783 GG | 4 | 4 |
| RS334353 GG | 6 | 11 |
| RS334353 GT | 41 | 45 |
| RS334353 TT | 78 | 71 |
| RS3812111 AA | 31 | 16 |
| RS3812111 AT | 57 | 52 |
| RS3812111 TT | 36 | 54 |
| RS429608 AA | 2 | 1 |
| RS429608 AG | 19 | 19 |
| RS429608 GG | 103 | 103 |
| RS4420638 AA | 89 | 96 |
| RS4420638 AG | 35 | 31 |
| RS4698775 GG | 11 | 8 |
| RS4698775 GT | 53 | 71 |
| RS4698775 TT | 60 | 47 |
| RS5749482 CC | 4 | 1 |
| RS5749482 CG | 26 | 26 |
| RS5749482 GG | 95 | 100 |
| RS6795735 CC | 43 | 37 |
| RS6795735 CT | 53 | 63 |
| RS6795735 TT | 28 | 27 |
| RS8017304 AA | 57 | 65 |
| RS8017304 AG | 53 | 51 |
| RS8017304 GG | 15 | 11 |
| RS8135665 CC | 68 | 79 |
| RS8135665 CT | 50 | 41 |
| RS8135665 TT | 6 | 7 |
| RS920915 CC | 32 | 33 |
| RS920915 CG | 64 | 60 |
| RS920915 GG | 28 | 34 |
| RS943080 CC | 27 | 35 |
| RS943080 CT | 57 | 64 |
| RS943080 TT | 40 | 28 |
| RS9542236 CC | 26 | 26 |
| RS9542236 CT | 61 | 63 |
| RS9542236 TT | 38 | 38 |
Assessed by Optical Coherence Tomography (OCT) and confirmed by a central reading centre.
| Participants | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| Month 12 | 3 | 2 |
| Month 24 | 1 | 2 |
Treatment requirements will be determined by the individual patient disease activity as measured by OCT, BCVA, colour fundus photography and fluorescein angiography (FA). Analysis was not performed.
| Visits | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen |
|---|---|---|
| The Number of Times a Participant Needs to Return to Monthly Treatments During the 24 Months. | 10.6 ± 8.34 | 7.6 ± 8.09 |
Collected over Up to 24 month. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intensive | 7/173 (4%) | 58/173 (33.5%) | 109/173 (63%) |
| Relaxed | 5/174 (2.9%) | 58/174 (33.3%) | 114/174 (65.5%) |
| Event | Intensive | Relaxed |
|---|---|---|
| PneumoniaInfections and infestations | 10/173 | 5/174 |
| Pneumonia(Non-ocular)Infections and infestations | 10/173 | 5/174 |
| Atrial fibrillationCardiac disorders | 2/173 | 7/174 |
| Atrial fibrillation(Non-ocular)Cardiac disorders | 2/173 | 7/174 |
| FallInjury, poisoning and procedural complications | 4/173 | 2/174 |
| Transient ischaemic attackNervous system disorders | 4/173 | 2/174 |
| Fall(Non-ocular)Injury, poisoning and procedural complications | 4/173 | 2/174 |
| Transient ischaemic attack(Non-ocular)Nervous system disorders | 4/173 | 2/174 |
| Cerebrovascular accidentNervous system disorders | 3/173 | 4/174 |
| Cerebrovascular accident(Non-ocular)Nervous system disorders | 3/173 | 4/174 |
| Event | Intensive | Relaxed |
|---|---|---|
| NasopharyngitisInfections and infestations | 23/173 | 29/174 |
| Nasopharyngitis(Non-ocular)Infections and infestations | 23/173 | 29/174 |
| Eye painEye disorders | 28/173 | 24/174 |
| InfluenzaInfections and infestations | 26/173 | 16/174 |
| Influenza(Non-ocular)Infections and infestations | 26/173 | 16/174 |
| Vitreous floatersEye disorders | 21/173 | 11/174 |
| FallInjury, poisoning and procedural complications | 21/173 | 15/174 |
| Fall(Non-ocular)Injury, poisoning and procedural complications | 21/173 | 15/174 |
| Age-related macular degenerationEye disorders | 18/173 | 17/174 |
| Lacrimation increasedEye disorders | 17/173 | 8/174 |
| Age, Continuous(Years) | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen | Total |
|---|---|---|---|
| Mean | 79.3 ± 8.12 | 78.8 ± 8.17 | 79 ± 8.12 |
| Sex: Female, Male(Participants) | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen | Total |
|---|---|---|---|
| Female | 100 | 89 | 189 |
| Male | 74 | 86 | 160 |
| Race (NIH/OMB)(Participants) | Intensive Retinal Fluid Regimen | Relaxed Retinal Fluid Regimen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 3 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 163 | 171 | 334 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2013 to primary completion in Feb 2017, 39 months.
Results were first posted in Oct 2019, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →